Oppenheimer Reiterates Outperform on CME Gr, Maintains $222 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Owen Lau has reiterated an 'Outperform' rating on CME Group (NASDAQ:CME) and maintained a price target of $222.
July 27, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated an 'Outperform' rating on CME Group and maintained a price target of $222.
The reiteration of an 'Outperform' rating by Oppenheimer indicates a positive outlook for CME Group. The maintained price target of $222 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100